Any current/future new fundraising through debt or equity?

There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript. The management discusses ongoing and upcoming CAPEX, particularly for Dombivli (around Rs. 150 crore) and Pune (Rs. 50+ crore) for FY26, but does not specify the funding source. They mention being mindful of "value we need to pay" for growth opportunities, implying caution on acquisitions or expansions. The focus seems to be on organic growth through existing and planned projects, with no explicit indication of immediate fundraising needs via debt or equity. For any off-announc

Any current/future capex/capital investment/strategic investment?

Current and near-future CAPEX primarily focused on two Greenfield projects: - Dombivli: Construction underway for a 500-bed hospital; expected operations start in calendar year 2026. - Pune: Regulatory approval expected in Q4 FY25 with construction to begin soon after. CAPEX estimates for FY26: - Dombivli requires approximately Rs. 150 crore. - Pune requires an additional Rs. 50+ crore. Existing facilities at Thane, Pune, and Indore are largely set in terms of CAPEX requirements for now. Expansion within existing hospitals includes adding 75-80 new beds in Indore, and 10-12 more beds p

Future growth expectations in sales/revenue/volumes?

Indore hospital is expanding by about 75-80 beds expected to start operations next quarter, contributing to revenue growth. Pune hospital added 22 beds recently, with scope to add 10-12 more beds, nearing full capacity. Indore's large land area (+5 acres) allows for expansion up to 200 beds depending on demand. New Greenfield projects in Dombivli (500 beds, operation expected by CY 2026) and Pune (awaiting regulatory approval; construction to start post Q4 FY25) will drive future growth. Bed occupancy at Indore increased from 57% in H1 FY25 to 61% in Q2 FY25, indicating rising utilization. Aft

Future growth expectations in earnings/operating earnings/profits/EPS?

Jupiter Life Line Hospitals anticipates continued growth driven by expansion projects, especially in Indore, Pune, and the new Dombivli hospital. Indore is adding 75-80 beds next quarter, expected to ramp up occupancy gradually. Second Pune hospital is in advanced regulatory stages; construction expected to start in Q4 FY25. EBITDA margins targeted around 25%, currently at ~23.6%; margins are expected to improve as new beds reach optimal occupancy. Operating profits are currently impacted by expansions at Indore and Pune but expected to grow as utilization increases. New projects require subst

Current/ Expected Orderbook/ Pending Orders?

Indore hospital has significant room for expansion with +5 acres of land and a semi-finished building capable of accommodating 100+ more beds; current commitment is about 200 beds but can be adjusted based on growth needs. Pune hospital recently added 22 beds and can still add 10 to 12 more beds before reaching maximum capacity. Two new Greenfield projects underway: - Dombivli (500 beds), construction progressing on schedule, operations expected to start in calendar year 2026. - Pune (under regulatory clearance), approvals expected by Q4 FY25, with construction to begin soon after. Ongo

Jupiter Life LinQ2 FY25Healthcare Services

Jupiter Life Lin Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹260P/E: 45.6Market Cap: ₹8.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Indore hospital is expanding by about 75-80 beds expected to start operations next quarter, contributing to revenue growth.
Pune hospital added 22 beds recently, with scope to add 10-12 more beds, nearing full capacity.
Indore's large land area (+5 acres) allows for expansion up to 200 beds depending on demand.
New Greenfield projects in Dombivli (500 beds, operation expected by CY 2026) and Pune (awaiting regulatory approval; construction to start post Q4 FY25) will drive future growth.
Bed occupancy at Indore increased from 57% in H1 FY25 to 61% in Q2 FY25, indicating rising utilization.
After capacity expansion, revenue volumes are expected to grow in absolute terms despite temporary percentage dips due to increased bed base.
EBITDA and PAT growth seen with aspirations to maintain EBITDA margin around 25%.

Margin guidance

Category 3

Jupiter Life Line Hospitals anticipates continued growth driven by expansion projects, especially in Indore, Pune, and the new Dombivli hospital.
Indore is adding 75-80 beds next quarter, expected to ramp up occupancy gradually.
Second Pune hospital is in advanced regulatory stages; construction expected to start in Q4 FY25.
EBITDA margins targeted around 25%, currently at ~23.6%; margins are expected to improve as new beds reach optimal occupancy.
Operating profits are currently impacted by expansions at Indore and Pune but expected to grow as utilization increases.
New projects require substantial CAPEX (Rs. 150 crore for Dombivli, Rs. 50+ crore for Pune in FY26).
Management prefers steady growth with multiple properties maturing at different stages, ensuring a continuous growth pipeline.
Overall, revenue, EBITDA, and PAT have shown robust YoY growth (~20-23% in revenue, ~22-23% EBITDA, ~9-53% PAT increase), suggesting strong future earnings momentum.

See what Jupiter Life Lin management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript.
The management discusses ongoing and upcoming CAPEX, particularly for Dombivli (around Rs. 150 crore) and Pune (Rs. 50+ crore) for FY26, but does not specify the funding source.
They mention being mindful of "value we need to pay" for growth opportunities, implying caution on acquisitions or expansions.
The focus seems to be on organic growth through existing and planned projects, with no explicit indication of immediate fundraising needs via debt or equity.
For any off-announced or new projects beyond current plans, funding details are not disclosed in this call.

Order book

Indore hospital has significant room for expansion with +5 acres of land and a semi-finished building capable of accommodating 100+ more beds; current commitment is about 200 beds but can be adjusted based on growth needs.
Pune hospital recently added 22 beds and can still add 10 to 12 more beds before reaching maximum capacity.
Two new Greenfield projects underway:
- Dombivli (500 beds), construction progressing on schedule, operations expected to start in calendar year 2026.
- Pune (under regulatory clearance), approvals expected by Q4 FY25, with construction to begin soon after.
Ongoing bed additions: 75-80 beds expected to be operational in Indore next quarter.
CAPEX plan for FY26 includes approximately Rs. 150 crore for Dombivli and Rs. 50+ crore for Pune development.
Existing facilities (Thane, Pune, Indore) are currently set in terms of CAPEX needs.

See what Jupiter Life Lin management said on order book — free account, 30 seconds.

Capex plans

Yes

Current and near-future CAPEX primarily focused on two Greenfield projects:
- Dombivli: Construction underway for a 500-bed hospital; expected operations start in calendar year 2026.
- Pune: Regulatory approval expected in Q4 FY25 with construction to begin soon after.
CAPEX estimates for FY26:
- Dombivli requires approximately Rs. 150 crore.
- Pune requires an additional Rs. 50+ crore.
Existing facilities at Thane, Pune, and Indore are largely set in terms of CAPEX requirements for now.
Expansion within existing hospitals includes adding 75-80 new beds in Indore, and 10-12 more beds possible in Pune.
No announced plans currently for inorganic growth or acquisitions, but management is open to opportunities if value aligns.

Track Jupiter Life Lin — get its next earnings analysis in your feed

How does Jupiter Life Lin rank vs peers in Healthcare Services?

Pro feature

ThisJupiter Life Lin

Rev 2Mar 3

See where Jupiter Life Lin sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Jupiter Life Lin rank in Healthcare Services?

Compare Jupiter Life Lin against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Jupiter Life Lin's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →